The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.
BMJ. 2013 Apr 18;346:f2032. doi: 10.1136/bmj.f2032.
To measure the effect on genital warts of the national human papillomavirus vaccination programme in Australia, which started in mid-2007.
Trend analysis of national surveillance data.
Data collated from eight sexual health services from 2004 to 2011; the two largest clinics also collected self reported human papillomavirus vaccination status from 2009.
Between 2004 and 2011, 85,770 Australian born patients were seen for the first time; 7686 (9.0%) were found to have genital warts.
Rate ratios comparing trends in proportion of new patients diagnosed as having genital warts in the pre-vaccination period (2004 to mid-2007) and vaccination period (mid-2007 to the end of 2011).
Large declines occurred in the proportions of under 21 year old (92.6%) and 21-30 year old (72.6%) women diagnosed as having genital warts in the vaccination period-from 11.5% in 2007 to 0.85% in 2011 (P<0.001) and from 11.3% in 2007 to 3.1% in 2011 (P<0.001), respectively. No significant decline in wart diagnoses was seen in women over 30 years of age. Significant declines occurred in proportions of under 21 year old (81.8%) and 21-30 year old (51.1%) heterosexual men diagnosed as having genital warts in the vaccination period-from 12.1% in 2007 to 2.2% in 2011 (P<0.001) and from 18.2% in 2007 to 8.9% in 2011 (P<0.001), respectively. No significant decline in genital wart diagnoses was seen in heterosexual men over 30 years of age. In 2011 no genital wart diagnoses were made among 235 women under 21 years of age who reported prior human papillomavirus vaccination.
The significant declines in the proportion of young women found to have genital warts and the absence of genital warts in vaccinated women in 2011 suggests that the human papillomavirus vaccine has a high efficacy outside of the trial setting. Large declines in diagnoses of genital warts in heterosexual men are probably due to herd immunity.
测量 2007 年中期在澳大利亚启动的全国人乳头瘤病毒(HPV)疫苗接种计划对生殖器疣的影响。
国家监测数据的趋势分析。
2004 年至 2011 年从 8 个性健康服务机构收集的数据;两个最大的诊所还从 2009 年开始收集自我报告的 HPV 疫苗接种情况。
2004 年至 2011 年期间,85770 名澳大利亚出生的患者首次就诊;其中 7686 名(9.0%)被诊断为生殖器疣。
比较疫苗接种前(2004 年至 2007 年年中)和接种期间(2007 年年中至 2011 年底)新患者中生殖器疣诊断比例的率比。
在接种期间,21 岁以下(92.6%)和 21-30 岁(72.6%)女性中被诊断为生殖器疣的比例大幅下降-从 2007 年的 11.5%降至 2011 年的 0.85%(P<0.001)和从 2007 年的 11.3%降至 2011 年的 3.1%(P<0.001);30 岁以上的女性生殖器疣诊断未见明显下降。在接种期间,21 岁以下(81.8%)和 21-30 岁(51.1%)异性恋男性中被诊断为生殖器疣的比例也大幅下降-从 2007 年的 12.1%降至 2011 年的 2.2%(P<0.001)和从 2007 年的 18.2%降至 2011 年的 8.9%(P<0.001);30 岁以上的异性恋男性生殖器疣诊断未见明显下降。2011 年,235 名报告有 HPV 疫苗接种史的 21 岁以下女性中,无一例生殖器疣被诊断。
在 2011 年,年轻女性生殖器疣的比例显著下降,且接种疫苗的女性中没有生殖器疣,这表明 HPV 疫苗在试验环境之外具有很高的疗效。异性恋男性生殖器疣诊断的大量减少可能归因于群体免疫。